Physicians' Academy for Cardiovascular Education

SGLT2 inhibitor reduces CV risk factors in patients with and without renal dysfunction

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

Literature - Petrykiv S, Sjöström DC, Greasley PJ, et al. - Clin J Am Soc Nephrol 2017; published online ahead of print

Main results

Conclusion

Dapagliflozin consistently reduced blood pressure, body weight and albuminuria, independently of baseline renal function. These findings suggest that further research of the long-term benefits of SGLT2 inhibitors in patients with diabetic kidney disease might be needed.

References

Show references

Find this article online at Clin J Am Soc Nephrol

Share this page with your colleagues and friends: